Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

Prior to novel targeted agents for chronic lymphocytic leukemia (CLL), the best chemoimmunotherapy regimen in patients with non-del(11q) disease was unclear. The role of lenalidomide was also not defined. This phase 2 study randomized 342 untreated patients with non-del(11q) CLL requiring therapy to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Byrd, John C., Ruppert, Amy S., Heerema, Nyla A., Halvorson, Alese E., Hoke, Eva, Smith, Mitchell R., Godwin, John E., Couban, Stephen, Fehniger, Todd A., Thirman, Michael J., Tallman, Martin S., Appelbaum, Frederick R., Stone, Richard M., Robinson, Sue, Chang, Julie E., Mandrekar, Sumithra J., Larson, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058242/
https://ncbi.nlm.nih.gov/pubmed/30030269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017015396
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados